Telix Pharmaceuticals appoints two new Non-Executive Directors to strengthen its board.

Telix Pharmaceuticals announced the appointment of two new Non-Executive Directors, Maria Rivas, MD, and William Jellison, effective May 11, 2026. These appointments aim to enhance the board's expertise in U.S. public company governance, financial oversight, and clinical leadership, supporting Telix's growth as a global biopharmaceutical company. The new directors bring extensive experience in pharmaceuticals, medical technology, and corporate finance. This move aligns with Telix's strategy to expand its board and succession planning as it advances its commercial and clinical operations worldwide.